Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial

被引:3
|
作者
Willcox, Merlin L. [1 ]
Hu, Xiao-Yang [1 ]
Oliver, Tom [2 ]
Thorne, Kerensa [2 ]
Boxall, Cherish [2 ]
He, George [3 ]
Simpson, Catherine [2 ]
Brotherwood, Becci [2 ]
O'Neil, Alice [2 ]
Waugh, Robert [2 ]
Tilt, Emma [2 ]
Trill, Jeanne [1 ]
Goward, Neville [4 ]
Francis, Nick [1 ]
Thomas, Michael [1 ]
Little, Paul [1 ]
Wilkinson, Tom [5 ]
Liu, Jian-Ping [6 ]
Griffiths, Gareth [2 ]
Moore, Michael [1 ]
机构
[1] Univ Southampton, Fac Med, Primary Care Res Ctr, Sch Primary Care Populat Sci & Med Educ, Southampton, Hants, England
[2] Univ Southampton, Southampton Clin Trials Unit, Southampton, England
[3] Phoenix Med Ltd, Chelmsford, Essex, England
[4] Patient & Publ Representat, Southampton, Hampshire, England
[5] Univ Southampton, Fac Med, Sch Clin & Expt Sci, Southampton, Hampshire, England
[6] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China
关键词
COPD; Chinese herbal medicine; feasibility clinical trial; Shufeng Jiedu capsule; acute exacerbation of chronic obstructive pulmonary disease; SHUFENG JIEDU CAPSULE; RESPIRATORY-INFECTION;
D O I
10.3389/fphar.2023.1221905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Although many acute exacerbations of COPD (AECOPD) are triggered by non-bacterial causes, they are often treated with antibiotics. Preliminary research suggests that the Chinese herbal medicine "Shufeng Jiedu" (SFJD), may improve recovery and therefore reduce antibiotic use in patients with AECOPD.Aims: To assess the feasibility of conducting a randomised placebo-controlled clinical trial of SFJD for AECOPD in UK primary care.Methods: GPs opportunistically recruited patients experiencing an AECOPD. Participants were randomised 1:1 to usual care plus SFJD or placebo for 14 days. Participants, GPs and research nurses were blinded to treatment allocation. GPs could prescribe immediate, delayed or no antibiotics, with delayed prescribing encouraged where appropriate. Participants were asked to complete a participant diary, including EXACT-PRO and CAT (TM) questionnaires for up to 4 weeks. Outcomes included recruitment rate and other measures of study feasibility described using only descriptive statistics and with no formal comparisons between groups. We also conducted qualitative interviews with recruited and non-recruited COPD patients and clinicians, analysed using framework analysis.Results: Over 6 months, 19 participants (6 SFJD, 13 placebo) were recruited. Sixteen (84%) participants returned diaries or provided a diary by recall. Overall, 1.3 participants were recruited per 1,000 patients on the COPD register per month open. Median duration of treatment was 9.8 days in the intervention group vs 13.3 days in the placebo group. The main reason for discontinuation in both groups was perceived side-effects. in both groups. Point estimates for both the EXACT-PRO and CAT (TM) outcomes suggested possible small benefits of SFJD. Most patients and clinicians were happy to try SFJD as an alternative to antibiotics for AECOPD. Recruitment was lower than expected because of the short recruitment period, the lower incidence of AECOPD during the COVID-19 pandemic, patients starting antibiotics from "rescue packs" before seeing their GP, and workforce challenges in primary care.Conclusion: Recruitment was impaired by the COVID-19 pandemic. Nevertheless, we were able to demonstrate the feasibility of recruiting and randomising participants and identified approaches to address recruitment challenges such as including the trial medication in COPD patients' "rescue packs" and delegating recruitment to a central trials team.Clinical Trial Registration: Identifier, ISRCTN26614726
引用
收藏
页数:14
相关论文
共 50 条
  • [31] RITUXIMAB OBJECTIVE OUTCOME MEASURES TRIAL IN SLE (ROOTS): A DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED FEASIBILITY TRIAL
    Mahmoud, K.
    Wilson, M.
    Yusof, M. Y. Md
    Brown, S.
    Hensor, E.
    Vital, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 202 - 202
  • [32] A preliminary randomised double-blind placebo-controlled clinical trial of hydroxyzine for treating sleep bruxism in children
    Ghanizadeh, A.
    Zare, S.
    JOURNAL OF ORAL REHABILITATION, 2013, 40 (06) : 413 - 417
  • [33] Dietary nitrate supplementation in COPD: An acute, double-blind, randomized, placebo-controlled, crossover trial
    Kerley, Conor P.
    Cahill, Kathleen
    Bolger, Kenneth
    McGowan, Aisling
    Burke, Conor
    Faul, John
    Cormican, Liam
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2015, 44 : 105 - 111
  • [34] Clinical efficacy of Chinese herbal medicine formula for Graves' hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial
    Gan, Di
    Gao, Tian-shu
    Ma, Li
    Lu, Hao
    Dai, Hong
    Liu, Qing-yang
    Lai, Yi-wen
    Liu, Xin-hui
    Peng, Ze-dong
    Chen, Ru-yu
    Qiu, Zi-yang
    Tong, Yu
    Yan, Ruo-xuan
    Liu, Jia-hui
    Shen, Qing
    Wang, Chen
    Yu, Shan-shan
    Chen, Si-wei
    Liu, Xiao-wei
    Chen, Xue-ying
    Zhang, Feng-nuan
    Wang, Zhi-min
    Wang, Ying-na
    Yang, Xiao
    JOURNAL OF ETHNOPHARMACOLOGY, 2025, 338
  • [35] The Efficacy of a Traditional Herbal Medicine Compound for Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Samimi, Soodabeh
    Nimrouzi, Majid
    Zarshenas, Mohammad Mehdi
    Fallahzadeh, Ebrahim
    Vardanjani, Hossein Molavi
    Sadeghi, Erfan
    Salehi, Zahra
    JUNDISHAPUR JOURNAL OF NATURAL PHARMACEUTICAL PRODUCTS, 2024, 19 (04)
  • [36] Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
    Besselink, Marc G. H.
    van Santvoort, Hjalmar C.
    Buskens, Erik
    Boermeester, Marja A.
    van Goor, Harry
    Timmerman, Harro M.
    Nieuwenhuijs, Vincent B.
    Bollen, Thomas L.
    van Ramshorst, Bert
    Witteman, Ben J. M.
    Rosman, Camiel
    Ploeg, Rutger J.
    Brink, Menno A.
    Schaapherder, Alexander F. M.
    Dejong, Cornelis H. C.
    Wahab, Peter J.
    van Laarhoven, Cees J. H. M.
    van der Harst, Erwin
    van Eijck, Casper H. J.
    Cuesta, Miguel A.
    Akkermans, Louis M. A.
    Gooszen, Hein G.
    LANCET, 2008, 371 (9613): : 651 - 659
  • [37] Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, double-blind, placebo-controlled trial
    Ukkonen, P
    Varis, K
    Jernfors, M
    Herva, E
    Jokinen, J
    Ruokokoski, E
    Zopf, D
    Kilpi, T
    LANCET, 2000, 356 (9239): : 1398 - 1402
  • [38] Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial
    Venkatesan, Thangam
    NUTRITION IN CLINICAL PRACTICE, 2008, 23 (06) : 662 - 663
  • [39] Probiotic prophylaxis In predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
    Besselink, M. G.
    van Santvoort, H. C.
    Buskens, E.
    Boermeester, M. A.
    van Goor, H.
    Timmerman, H. M.
    Nieuwenhuijs, V. B.
    Bollen, T. L.
    van Ramshorst, B.
    Witteman, B. J.
    Rosman, C.
    Ploeg, R. J.
    Brink, M. A.
    Schaapherder, A. F.
    Dejong, C. H.
    Wahab, P. J.
    van Laarhoven, C. J.
    van der Harst, E.
    van Eijck, C. H.
    Cuesta, M. A.
    Akkermans, L. M.
    Gooszen, H. G.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A8 - A9
  • [40] Randomized, Double-Blind, Placebo-Controlled Trial of Herbal Therapy for Children with Asthma
    Wong, Eliza L. Y.
    Sung, Rita Yn Tz
    Leung, Ting Fan
    Wong, Yeuk Oi
    Li, Albert M. C.
    Cheung, Kam Lau
    Wong, Chun Kwok
    Fok, Tai Fai
    Leung, Ping Chung
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2009, 15 (10) : 1091 - 1097